Company Overview

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of recombinant therapeutic proteins produced through its proprietary plant cell–based protein expression platform, known as ProCellEx. The company operates within the biotechnology and rare disease sectors, with a strategic emphasis on treatments for lysosomal storage disorders, immunology-related conditions, and other specialty indications. Its core revenue drivers include product sales, licensing arrangements, supply agreements, and collaboration-related payments tied to commercialized and pipeline therapies.

The company is best known for developing taliglucerase alfa, marketed as Elelyso for Gaucher disease, which became the first FDA-approved plant cell–expressed recombinant therapeutic protein. Protalix has evolved from an early-stage platform biotechnology company into a commercial-stage organization with both marketed products and clinical-stage candidates. Its positioning is differentiated by its plant cell–based manufacturing system, which management states may offer advantages in scalability, production flexibility, and potentially lower manufacturing costs compared with traditional mammalian cell systems.

Business Operations

Protalix conducts operations primarily through its biotechnology research, development, and biologics manufacturing activities. Its business model centers on proprietary protein expression technology, internal drug development programs, strategic collaborations, and manufacturing capabilities. Key assets include the ProCellEx expression system and related biologics manufacturing infrastructure. The company’s commercial activities include sales associated with Elelyso and collaboration revenues linked to development and commercialization agreements. Major pipeline programs have included pegunigalsidase alfa for Fabry disease and PRX-115 for gout-related indications.

Internationally, Protalix has partnered with larger pharmaceutical organizations for commercialization and distribution activities. The company has maintained a significant collaboration with Chiesi Global Rare Diseases, which has been involved in the development and commercialization of pegunigalsidase alfa in multiple territories. Manufacturing operations are primarily based in Israel, while commercial reach extends into North America, Latin America, Europe, and other selected international markets through partnership arrangements and licensing agreements.

Strategic Position & Investments

Protalix’s strategic direction has focused on leveraging its plant-based biologics platform to expand its rare disease portfolio while reducing dependence on a single commercial product. The company has invested in advancing late-stage clinical assets, particularly in Fabry disease, where pegunigalsidase alfa has represented a major strategic priority. Regulatory submissions and commercialization partnerships have been central to its growth strategy, alongside efforts to broaden the applicability of its expression technology into additional therapeutic categories.

The company’s strategic collaborations have played a major role in financing development activities and extending commercial reach. Agreements involving Chiesi Global Rare Diseases and prior collaborations with larger pharmaceutical entities have provided milestone payments, development support, and regional commercialization capabilities. Protalix has also emphasized intellectual property protection surrounding its ProCellEx technology platform and manufacturing methods. Public disclosures in SEC filings and company investor materials indicate ongoing investment in pipeline expansion and lifecycle management for existing biologic candidates.

Geographic Footprint

Protalix is headquartered in Carmiel, Israel, with operational and manufacturing activities concentrated there. The company also maintains a corporate presence in the United States, where it accesses capital markets and supports commercial and regulatory activities. Its therapies and development programs have regulatory and commercial relevance across multiple international jurisdictions.

The company’s commercial footprint spans regions including North America, Latin America, and parts of Europe through licensing and commercialization agreements. Elelyso has been marketed in several countries for Gaucher disease treatment, while pipeline programs have pursued regulatory pathways with agencies including the U.S. Food and Drug Administration and the European Medicines Agency. Protalix’s international strategy relies heavily on partnerships rather than wholly owned commercial infrastructure outside its core operating base.

Leadership & Governance

Protalix was co-founded by entrepreneurs and scientists involved in advancing plant cell–based biotechnology applications for therapeutic protein production. The company is publicly traded on the NYSE American under the ticker PLX and operates under a governance structure typical of U.S.-listed biotechnology companies, with executive leadership overseeing research, manufacturing, regulatory affairs, and commercial strategy. Management communications and public filings emphasize disciplined capital allocation, advancement of rare disease therapies, and maximizing the strategic value of the company’s proprietary biologics platform.

Key executives and leadership figures include:

• Dror Bashan – President and Chief Executive Officer
• Efrat Katri – Senior Vice President and Chief Financial Officer
• Einat Brill Almon, Ph.D. – Senior Vice President and Chief Development Officer
• David Aviezer, Ph.D. – Chairman of the Board
• Yehiel Tal – Vice President, Plant Operations

The company’s leadership has consistently emphasized rare disease therapeutics, platform validation through regulatory approvals, and strategic partnerships as central components of its long-term operating philosophy.